We claim:

1. A compound according to formula I:



I

wherein,

R-O- is a residue of a ~~an alcohol containing or~~ phenol-containing pharmaceutical compound, excluding taxol,

R^1 is hydrogen or an alkali metal ion or a protonated amine or a protonated amino acid,

R^2 is hydrogen or an alkali metal ion or a protonated amine or a protonated amino acid, and

n is an integer of 1 or 2;

and pharmaceutically acceptable salts thereof.

2. The compound according to claim 1, wherein said alcohol-containing or phenol-containing compound is selected from the group consisting of camptothecin, camptothecin analogues, propofol, etoposide, vitamin E and cyclosporin A.

3. The compound according to claim 1, wherein the alkali metal ion of R^1 and R^2 is each independently selected from the group consisting of sodium, potassium and lithium.

4. A compound selected from the group consisting of:







Cyclosporin A





and



wherein Z is selected from the group consisting of hydrogen, alkali metal ion, and amine;

and pharmaceutically acceptable salts thereof.

5. The compound according to claim 4, wherein each Z is independently selected from the group consisting of sodium, tromethamine, triethanolamine, triethylamine, arginine, lysine, ethanolamine and N-methylglucamine.

6. A compound according to formula III:



(III)

wherein,

R-O- is a residue of an alcohol-containing or phenol-containing pharmaceutical compound, excluding taxol;

and pharmaceutically acceptable salts thereof.

7. A compound according to claim 6, wherein said compound is selected from the group consisting of:



,



,



Cyclosporin A

,



,



and



8. A compound according to formula IV:



(IV)

wherein,

R-O- is a residue of ~~an alcohol-containing or~~ phenol-containing pharmaceutical compound, excluding taxol,

Y is a phosphono protecting group, and

n is an integer of 1 or 2;

and pharmaceutically acceptable salts thereof.

9. A compound according to claim 8, wherein said compound is selected from the group consisting of:



,



,



Cyclosporin A

,



,



and



wherein Y is a phosphono protecting group.

10. The compound according to claim 8, wherein said phosphono protecting group is selected from the group

consisting of a benzyl group, a t-butyl group, an allyl group, and other acceptable phosphate protecting groups.

11. A pharmaceutical composition, comprising:

~~an effective amount of~~ a compound according to claim 1; and

a pharmaceutically acceptable carrier.

12. A process for preparing a compound of claim 4, comprising:

removing a phosphono protecting group from a compound according to one of the following formula:







Cyclosporin A





and



wherein Y is the phosphono protecting group; and

recovering the product.

13. A process for preparing a compound of claim 6, comprising:

reacting a compound of the formula R-O-H,

63

wherein,

R-O- is a residue of an alcohol-containing or phenol-containing pharmaceutical compound, excluding taxol,

and pharmaceutically acceptable salts thereof,

with dimethylsulfoxide in the presence of acetic anhydride and acetic acid; and

recovering the product.

14. A process for preparing a compound of claim 7, comprising:

reacting a compound according to formula III:



(III)

wherein,

R-O- is a residue of an alcohol-containing or phenol-containing pharmaceutical compound, excluding taxol; and

pharmaceutically acceptable salts thereof,

with N-iodosuccinamide and a protected phosphoric acid of formula HOP(O)(OY), wherein Y is a phosphono protecting group; and

recovering the product.

15. The process according to claim 14, wherein the phosphono protecting group is selected from the group consisting of a benzyl group, a t-butyl group and an allyl group.

16. A method of treatment which comprises administering to a patient in need thereof an effective amount of a composition according to claim 11.

Rule 126 12 17. The method according to claim ~~16,~~ 11 wherein said compound is administered orally.

13 ~~18~~. The method according to claim ~~16,~~ 11 wherein said compound is administered parenterally.